Sundar PichaiSundar Pichai earned $164M in 2023

George A. Scangos is the former CEO of Biogen, where he served from July 2010 to July 2016. He advanced the company significantly during his tenure, focusing on biotechnology innovations and strategic growth. Before joining Biogen, he had notable experience...

Quick Links
B

George A. Scangos

Ex-CEO of Biogen

Education

Ph.D. in Microbiology from the University of Massachusetts

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1953 - 72 years ago

CEO of Biogen for

5 years 11 months (Jul 2010 - Jul 2016)

Previous Experience

President and Chief Executive Officer of Exelixis, Inc.

Holdings

See how much did George A. Scangos make over time.

During his time at Biogen, Scangos had substantial holdings in Biogen common stock, with significant fluctuations noted. For instance, in September 2019, his stock's value was around $25.22 million, showing a promising growth trajectory. However, by March 2023, it had...

Total Stock Sold

$54.03M

EXEL

$23.50M

1,114,894 EXEL shares

BIIB

$30.53M

118,894 BIIB shares

What if they kept their stock?

If George A. Scangos didn't sell their stock, today they would have:
Extra EXEL1,114,894 shares worth $19.82M and BIIB118,894 shares worth $38.40M.
This is 7.75% and $4.19M more than what they got when they sold the stock.

Charitable Transactions

BIIB

10,756 shares

BIIB

EXEL

12,500 shares

EXEL

Recent Charitable Transactions

EXEL

12,500 shares

EXEL

Dec 27, 2019

Charity

EXEL

13,950 shares

EXEL

Jan 2, 2019

Charity

BIIB

10,756 shares

BIIB

Nov 29, 2012

Charity

Insider Trading

See recent insider trades of George A. Scangos.

EXEL

$1.95M

EXEL at $25.96/share

May 18, 2020

Sale

EXEL

$3.00M

EXEL at $26.05/share

Apr 23, 2020

Sale

EXEL

$1.47M

EXEL at $24.45/share

Apr 20, 2020

Sale

EXEL

$457.75K

EXEL at $18.31/share

Apr 15, 2020

Sale

EXEL

$430.05K

EXEL at $18.30/share

Apr 7, 2020

Sale

EXEL

$27.09K

EXEL at $18.06/share

Mar 31, 2020

Sale

EXEL

$1.04M

EXEL at $20.73/share

Feb 18, 2020

Sale

EXEL

$502.00K

EXEL at $20.08/share

Feb 11, 2020

Sale

EXEL

$493.75K

EXEL at $19.75/share

Jan 22, 2020

Sale

EXEL

$509.75K

EXEL at $20.39/share

Jan 15, 2020

Sale

Compensation History

See how much did George A. Scangos make over time.

In terms of compensation, during his final full year at Biogen in 2016, George A. Scangos earned about $5.8 million. This included a base salary of $1 million and additional bonuses tied to the company’s performance measures like operating income and revenue growth. His compensation strategy was designed to align his success with the company's financial health, incentivizing him to lead Biogen effectively. Notably, he had a solid salary but received most of his earnings from stock options and performance-based bonuses. The years leading up to his departure, he benefited from a substantial amount of vested stock options, indicating not only his success but also a strong expected future for the company. His pay structure reflects a philosophy where executive rewards are tied closely to shareholder success.

Year

2016

Total Compensation

$5.80M

Salary

$1.00M

Board Justification

The compensation philosophy aligns with company performance, peer benchmarking, and retention strategies to attract and retain top executive talent.

Bonus

$500.00K

Board Justification

Annual cash bonus based on performance metrics including revenue growth and operating income for the year 2016.

Other

$300.00K

Board Justification

Other compensation includes retirement contributions and insurance premiums paid by the company.

Restricted Stock

$4.00M(20K Common Stock)

Board Justification

Vested stock options from previous grants that became exercisable in 2016.

Performance Metrics

Performance metrics included revenue growth, operating income, and achievement of strategic goals.